Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Reducing the immunogenicity of CRISPR-Cas9 technology with Tregs

Lena Peter • 1 Apr 2022
ICLE 2022
General

Gene therapies based on CRISPR-Cas9 technology currently face issues relating to immunogenicity due to preexisting immunity to Cas9 proteins. Lena Peter, Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany, comments on promoting the immune tolerance of CRISPR-Cas9-based gene therapies. Gene therapies utilizing in vivo gene editing will particularly be affected as a result of T-cell mediated immune responses. However, Cas9-specific regulatory T cells (Tregs) can potentially ameliorate the immunogenic effects of effector T cells, and should be further investigated to guide decision making in clinical trials. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

More from Lena Peter

4:06
Treating COVID-19 with modified T-cells for immunocompromised patients
Lena Peter • 1 Apr 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals